Your browser is no longer supported. Please, upgrade your browser.
Index- P/E- EPS (ttm)-3.79 Insider Own- Shs Outstand22.84M Perf Week-49.07%
Market Cap94.47M Forward P/E- EPS next Y- Insider Trans- Shs Float7.46M Perf Month-49.75%
Income-77.00M PEG- EPS next Q- Inst Own7.80% Short Float0.21% Perf Quarter-28.69%
Sales4.80M P/S19.68 EPS this Y-14.10% Inst Trans- Short Ratio0.01 Perf Half Y-58.57%
Book/sh1.85 P/B1.63 EPS next Y- ROA- Target Price17.75 Perf Year-50.93%
Cash/sh1.74 P/C1.74 EPS next 5Y- ROE- 52W Range3.20 - 13.00 Perf YTD-67.28%
Dividend- P/FCF- EPS past 5Y- ROI-138.90% 52W High-76.77% Beta2.48
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low-5.63% ATR0.45
Employees196 Current Ratio2.30 Sales Q/Q27.80% Oper. Margin- RSI (14)15.84 Volatility9.81% 5.90%
OptionableYes Debt/Eq0.57 EPS Q/Q37.20% Profit Margin- Rel Volume0.53 Prev Close3.29
ShortableYes LT Debt/Eq0.52 EarningsSep 20 AMC Payout- Avg Volume1.13M Price3.02
Recom1.70 SMA20-48.30% SMA50-49.39% SMA200-56.00% Volume592,754 Change-8.21%
Oct-25-21 12:11PM  
Oct-07-21 12:00PM  
Oct-04-21 04:05PM  
Sep-28-21 04:05PM  
Sep-22-21 12:30PM  
Sep-20-21 04:05PM  
Sep-15-21 04:05PM  
Sep-06-21 04:05PM  
Sep-03-21 12:00PM  
Aug-30-21 04:05PM  
Aug-24-21 04:30PM  
Aug-05-21 12:00PM  
Jul-30-21 08:50AM  
Jul-29-21 04:05PM  
Jul-27-21 01:30AM  
Jul-21-21 04:05PM  
Jul-06-21 12:00PM  
Jun-25-21 04:30PM  
Jun-07-21 12:00PM  
May-26-21 04:30PM  
May-25-21 04:00PM  
May-07-21 12:00PM  
May-04-21 04:30PM  
Apr-29-21 02:30AM  
Apr-28-21 07:30PM  
Apr-20-21 01:30AM  
Apr-19-21 01:30AM  
Apr-07-21 04:30PM  
Mar-09-21 04:30PM  
Mar-08-21 04:30PM  
Mar-05-21 12:00PM  
Mar-04-21 04:30PM  
Feb-24-21 04:30PM  
Feb-10-21 04:30PM  
Feb-08-21 01:30AM  
Feb-04-21 01:00PM  
Jan-25-21 04:30PM  
Jan-14-21 04:30PM  
Jan-13-21 08:36AM  
Jan-06-21 04:30PM  
Jan-04-21 02:00AM  
Dec-14-20 04:30PM  
Dec-10-20 04:30PM  
Dec-07-20 02:00AM  
Dec-03-20 04:30PM  
Nov-12-20 04:30PM  
Nov-05-20 04:30PM  
Nov-04-20 12:00PM  
Nov-02-20 03:19AM  
Oct-29-20 05:30PM  
Oct-26-20 05:30PM  
Oct-12-20 05:51AM  
Sep-21-20 04:45PM  
Sep-16-20 04:30PM  
Sep-14-20 04:30PM  
Aug-06-20 12:00PM  
Jul-10-20 12:00PM  
Jun-26-20 04:30PM  
Jun-25-20 08:26AM  
Jun-09-20 12:00PM  
Jun-02-20 04:30PM  
Jun-01-20 01:30AM  
May-26-20 04:00PM  
May-07-20 12:00PM  
May-06-20 04:30PM  
May-05-20 04:30PM  
Apr-30-20 04:30PM  
Apr-28-20 06:13PM  
Apr-20-20 04:30PM  
Apr-06-20 12:00PM  
Mar-19-20 06:00PM  
Mar-16-20 06:05PM  
Mar-12-20 05:30PM  
Mar-06-20 12:00PM  
Feb-26-20 05:00PM  
Feb-20-20 04:30PM  
Feb-04-20 12:00PM  
Feb-03-20 06:43AM  
Jan-24-20 01:30AM  
Jan-14-20 08:29AM  
Jan-10-20 11:45AM  
Dec-02-19 12:00PM  
Nov-25-19 01:30AM  
Nov-14-19 05:00PM  
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.